期刊
OBESITY SURGERY
卷 18, 期 8, 页码 1000-1006出版社
SPRINGER
DOI: 10.1007/s11695-007-9369-7
关键词
visfatin; bariatric surgery; morbid obesity; diabetes mellitus; weight loss; polycystic ovary syndrome; insulin resistance
类别
资金
- Spanish Ministry of Health and Consumer Affairs
- Instituto de Investigacion Carlos III [FIS P1050341]
- REDIMET [RD06/0015/0007]
Background Previous Studies addressin the changes in 9 0 serum visfatin levels after bariatric Surgery yielded conflicting results. Methods We measured serum visfatin levels in 41 morbidly obese women before bariatric surgery and after losing at least 15% of the initial weight.. and analyzed the results taking into account the type of surgery, reproductive and diabetic status, among others. Body mass index, waist circumference, lipid profile, and insulin resistance determined by homeostasis model assessment (HOMA-IR) were also measured. Results Patients lost 30.3 +/- 6.1 % of the initial body weight, and serum visfatin levels increased from 22.2 +/- 20.9 to 32.2 +/- 27.6 ng/ml (P=0.031). A multiple regression model (R-2 = 0.314. F=3.555, P=0.017) including the percentage of weight loss, changes in waist circumference, HOMA-IR, high-density lipoprotein-cholesterol, and triglycerides (also expressed as percentage from baseline), the Surgical procedure, time elapsed since Surgery, and previous diabetic status as independent variables showed that weight loss (beta=-0.670, P=0.010), previous diabetic status (beta=-0.330, P=0.036), and change in waist circumference (beta=0.556, P=0.031) were the main determinants of the percentual increase in serum visfatin levels observed after bariatric surgery. Conclusion Serum visfatin increased after bariatric surgery in relation to the amount of weight lost and to the changes in waist circumference, and this increase was higher in diabetic patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据